Trabectedin for desmoplastic small round cell tumours: a possible treatment option?

Clinical Sarcoma Research

Palma Dileo¹  Jeremy S Whelan¹  Anna Maria Frezza² 

[1] The London Sarcoma Service, University College Hospital, 1st Floor Central, 250 Euston Road, London NW1 2PG, UK;Medical Oncology, University Campus Bio-Medico, Rome, Italy

关键词: Chemotherapy;    Trabectedin;    Desmoplastic small round cell tumor;    Sarcoma;   

Others  :  861282
DOI  :  10.1186/2045-3329-4-3

 received in 2014-01-19, accepted in 2014-04-14,  发布年份 2014

【 摘 要 】

Background

Desmoplastic small round cell tumour (DSRCT) is a rare sarcoma typically affecting young males and usually widely metastatic at presentation. Despite multimodal treatment approaches, the prognosis for DSRCT is extremely poor. Alkylator- and anthracyclines- based regimens are widely used as therapy and an initial response is common. Durable responses are exceptionally rare so further systemic treatment options for these patients represent an unmet medical need. We report two cases of metastatic, pretreated DSRCT patients achieving disease stabilisation with Trabectedin.

Methods

Retrospective review of 2 patients with progressive DSRCT, treated with Trabectedin.

Results

Two males aged 19 and 23 years treated with Trabectedin, 1.5 mg/m² over 24 hours 3 weekly for 6 and 5 cycles respectively. Best responses were stable disease in patient 1 and partial response (RECIST 1.1) in patient 2. Progression free survival was 4 months in both cases. Persistent neutropenia required 4 weekly administration in one patient but no other grade 3-4 toxicities occurred.

Conclusions

This report supports Trabectedin to be active and safe in pre-treated DSRCT patients. Further prospective and collaborative efforts are desirable to better define its role in the management of this disease.

【 授权许可】

   
2014 Frezza et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Worch J, Cyrus J, Goldsby R, Matthay KK, Neuhaus J, DuBois SG: Racial differences in the incidence of mesenchymal tumors associated with EWSR1 translocation. Cancer Epidemiol Biomarkers Prev 2011, 20(3):449-453.
• [2]Fletcher CDM, Unni K, Mertens F: Pathology and genetics of tumours of soft tissue and bone. World Health Organization Classification of Tumours. Lyon: IARC press; 2002.
• [3]Ladanyi M, Gerald W: Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor. Cancer Res 1994, 54:2837-2840.
• [4]Kushner BH, LaQuaglia MP, Wollner N, Meyers PA, Lindsley KL, Ghavimi F, Merchant TE, Boulad F, Cheung NK, Bonilla MA, Crouch G, Kelleher JF Jr, Steinherz PG, Gerald WL: Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy. J Clin Oncol 1996, 14(5):1526-1531.
• [5]Hassan I, Shyyan R, Donohue JH, Edmonson JH, Gunderson LL, Moir CR, Arndt CA, Nascimento AG, Que FG: Intraabdominal desmoplastic small round cell tumors: a diagnostic and therapeutic challenge. Cancer 2005, 104(6):1264-1270.
• [6]Pinnix CC, Fontanilla HP, Hayes-Jordan A, Subbiah V, Bilton SD, Chang EL, Grosshans DR, McAleer MF, Sulman EP, Woo SY, Anderson P, Green HL, Mahajan A: Whole abdominopelvic intensity-modulated radiation therapy for desmoplastic small round cell tumor after surgery. Int J Radiat Oncol Biol Phys 2012, 83(1):317-326.
• [7]Lal DR, Su WT, Wolden SL, Loh KC, Modak S, La Quaglia MP: Results of multimodal treatment for desmoplastic small round cell tumors. J Pediatr Surg 2005, 40(1):251-255.
• [8]Grosso F, Sanfilippo R, Virdis E, Piovesan C, Collini P, Dileo P, Morosi C, Tercero JC, Jimeno J, D’Incalci M, Gronchi A, Pilotti S, Casali PG: Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol 2009, 20(8):1439-1444.
• [9]Forni C, Minuzzo M, Virdis E, Tamborini E, Simone M, Tavecchio M, Erba E, Grosso F, Gronchi A, Aman P, Casali P, D’Incalci M, Pilotti S, Mantovani R: Trabecedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther 2009, 8(2):449-457.
• [10]Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, Pasqualini F, Grosso F, Sanfilippo R, Casali PG, Gronchi A, Virdis E, Tarantino E, Pilotti S, Greco A, Nebuloni M, Galmarini CM, Tercero JC, Mantovani A, D’Incalci M, Allavena P: Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res 2010, 70(6):2235-2244.
• [11]Grohar PJ, Griffin LB, Yeung C, Chen QR, Pommier Y, Khanna C, Khan J, Helman LJ: Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. Neoplasia 2011, 13(2):145-153.
• [12]Dileo P, Sanfilippo R, Grosso F, Fumagalli E, Blay JY, Domont J, Le Cesne A, Tercero JC, Casali PG: Trabectedin (T) in advanced, pretreated synovial sarcomas (SS): A retrospective analysis of 39 patients (pts) from three European institutions. J Clin Oncol 2010, 28:15s. suppl; abstr 10030
• [13]López-González A, Cantos B, Tejerina E, Provencio M: Activity of trabectidin in desmoplastic small round cell tumor. Med Oncol 2011, 28(Suppl 1):S644-S646.
• [14]Chuk MK, Aikin A, Whitcomb T, Widemann BC, Zannikos P, Bayever E, Balis FM, Fox E: A phase I trial and pharmacokinetic study of a 24-hour infusion of Trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors. Pediatr Blood Cancer 2012, 59(5):865-869.
• [15]Whelan J, Khan A, Sharma A, Rothermundt C, Dileo P, Michelagnoli M, Seddon B, Strausss S: Interval compressed vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide, etoposide in patients with advanced Ewing’s and other small round cell sarcomas. Clin Sarcoma Res 2012, 2(1):12. doi:10.1186/2045-3329-2-12